Lung Injury Pipeline Insights, 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Lung Injury - Pipeline Insights, 2017" drug pipelines to their offering.

Lung Injury - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Lung Injury. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Lung Injury.

The report also assesses the Lung Injury therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

• The report provides competitive pipeline landscape of Lung Injury
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Lung Injury pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Lung Injury and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

1. Overview
2. Pipeline Therapeutics
3. Therapeutics under Development by Companies
4. Filed and Phase III Products
5. Phase II Products
6. Phase I and IND Filed Products
7. Discovery and Pre-Clinical Stage Products
8. Drug Candidate Profiles
9. Therapeutics Assessment
10. Assessment by Monotherapy Products
11. Assessment by Combination Products
12. Assessment by Route of Administration
13. Assessment by Molecule Type
14. Discontinued Products
15. Dormant Products
16. Companies Involved in Therapeutics Development

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/t2hglk/lung_injury